Introduction
Candida bloodstream infections (BSI) have become a major healthcare problem, specially in tertiary-care hospitals worldwide (Al- . Several risk factor identified among patients hospitalized for long periods such as the exposition to broad spectrum antimicrobial and/or immunosuppressive chemotherapy, parenteral nutrition, and invasive medical procedures have contributed to this fact (Blumberg et al., 2001 , Fraser et al., 1992 . Despite some improvements in fungal BSI diagnosis during last years, candidemia diagnosis remains difficult. Besides, following the data appeared in the classical study from Berenguer and colleagues, only 50% of patients with disseminated candidiasis will have positive blood cultures and even fewer will have an antemortem diagnosis (15% to 40%) (Berenguer et al., 1993) . Therefore, invasive candidemia is not easy to diagnose, has an expensive treatment and finally is a serious, often lifethreatening infection (Girmenia et al., 1996 , Messer et al., 2009 ).
Although the incidence of candidemia has increased steadily among hospitalized patients during the eighties and nineties, recent series suggest that This increase has stabilized, but with great variations between different geographical locations with similar socio-economical development even in the same continent. For instance, in The Netherlands an increasing incidence of candidemia has been reported during the period between eighties and nineties (Voss et al., 1996) but on the other hand, in a neighbouring country such as Switzerland the incidence of Candida BSI infections remained unchanged during the same period (Marchetti et al., 2004) . Therefore, it seems that there are some differences in the epidemiology of candidemia between different countries.
Besides, in recent years, a trend towards increasing resistance to both traditional and more recently introduced antifungal agents has been observed amongst invasive Candida infections, underscoring the need for continuous surveillance to monitor trends in incidence, species distribution, and antifungal drug susceptibility profiles.
Table 1. Definitions according to NHSN (formerly NISS) used in this study

In vitro susceptibility testing
Antifungal susceptibility tests were performed by using the broth microdilution assay according to the methodology recommended by the CLSI (formerly known as NCCLS), document M27-A2 (NCCLS, 2002) using a microtiter plate. Each isolate was tested against different antifungal drugs at the indicated concentration range suggested in the CLSI document. Quality control (QC) was ensured by testing the CLSI recommended QC strains, C. krusei ATCC 6258, and C. parapsilosis ATCC 22019.The MIC endpoint for amphotericin B, azoles and echinocandins and interpretative MIC breakpoints for azoles and echinocandins were those suggested by the CLSI document M27-A2, but for the definition of the amphotericin B MIC breakpoints we used the values suggested from a previous study published by Nguyen et al. (Nguyen et al., 1998) .
Statistical analysis
The numbers of admissions and patient-days were collected to calculate incidence rates. The incidence rate for each hospital was calculated as the number of candidemias per 1,000 admissions, whereas the overall incidence was determined using summed denominators of patient-days and admissions to calculate pooled mean rates. The data generated during the year of the surveillance on the different risk factors, underlying diseases, morbidity and mortality were recorded in a Microsoft Access 2003 (Microsoft Corporation, Redmond, WA) based case report database. Categorical data were analyzed using Chi-square or Fisher's exact tests as appropriate, and continuous variables were compared using the t-test or Wilcoxon test according to the significance of the normality test. Spearman rank-order correlation was used to measure the relationship between the MICs of fluconazole and voriconazole. We performed univariate and multivariate analysis of factors associated with candidemia caused by isolates with decreased susceptibility to fluconazole. Variables significant at p-values of less than 0.05 by univariate analysis were included in a multivariate model using a repeated measures logistic regression model (backward and forward). Data were analyzed using the SPSS 11.0.1 software (SPSS, Inc. Chicago, IL) and Stata 8.0 (Stata Corporation, Lenexa, TX).
Distribution of Candida blodostream infections
During the 12-month study period a total of 984 Candida BSIs were reported. The calculated overall incidence was 1.09 cases per 1,000 admissions, however the incidence rate changed a lot between the 40 centers enrolled in this study and ranged from 0.76 to 1.49 cases per 1,000 admissions.
Among the invasive Candida BSIs, 45.3 % occurred in patients in an medical service, 23.5% in patients hospitalized in an intensive care unit, 17.6% in patients in a surgical ward, 7.41% in a pediatric ward and finally 4.06% in other services. Most of the patients (98.7%) were hospitalized and only nine of them were outpatients at the time of diagnosis.
Candidemia incidence was slightly higher in males (64.02% of the case patients) and the global average age at the onset of the episode was 41 years with a median age was 53 years among adult patients and 7 months among children.
The frequency of BSIs due to the most frequently isolated species of Candida in the study sites are presented in Table 2 Overall, the 49.08% of the cases were attributable to C. albicans, 20.73% were attributable to C. parapsilosis, 13.61% were attributable to C. glabrata, 10.77% were attributable to C. tropicalis, 2,13% to C. krusei and the rest of the cases (3.65%) were attributable to other species. The distribution of Candida species among adult population was similar to the one found in pediatric cases, however, the distribution of species varied considerably when analyzed between centers as it has been reflected in the ranges specified in Table 2 . The species distribution among our study isolates is similar to that described by Pfaller et al. (Pfaller et al., 1998) in Latin America with data collected by the Sentry Antimicrobial Surveillance Program. As Pfaller and colleagues described previously, the proportion of species isolated varies considerably among medical centers beign unclear the reasons for such differences and they could be attributed to many different influences. There were no statistically significant differences when the risk mentioned above were analyzed for the pediatric population of patients.
Antifungal susceptibility
In vitro susceptibility testing of the 984 BSI isolates of Candida species against amphotericin B, fluconazole, voriconazole, caspofungin and anidulafungin revealed that when globally analyzed Candida strains causing BSI are rarely resistant to a wide number of antifungal agents. However, the resistance rates among the different species vary a lot as it can be shown on Table 4 . The antifungal activities of voriconazole, fluconazole, amphotericin B, caspofungin and anidulafungin against the 984 Candida spp isolated during the study period are summarized in Table 4 . Among the azole compounds, voriconazole was the most active drug overall with an MIC90 of 0.25 µg/ml. Against C. albicans, C. parapsilosis and C. tropicalis isolates, voriconazole (MIC90 range 0.03-0.25 µg/ml) was much more active than fluconazole (MIC90, 2-4). Although these differences in the drug activity, both azole compounds showed lower MICs for fluconazole and voriconazole for the species mentioned before when compared to C. glabrata and C. krusei isolates. Despite this good susceptibility profile, we found five Candida albicans isolates with a MIC greater than 4 µg/ml to voriconazole and two C. krusei isolates that had a voriconazole MIC of 2 ug/ ml. All these isolates were also resistant to fluconazole.
We found that there was a statistically significant moderate linear correlation between fluconazole and voriconazole MICs (r = 0.574; P ≤ 0.01). having higher voriconazole MICs those isolates from patients who received fluconazole before the candidemia episode when compared to those without previous exposure to fluconazole (MIC90s of 0.25 µg/ml and 0.06 µg/ml, respectively; P ≤ 0.05 We found that this condition was associated with neoplasia (9% versus 3%; P ≤ 0.01), current neutropenia (16% versus 4%; P ≤ 0.01), and prior fluconazole use (14% versus 3%; P ≤ 0.001). These independent factors identified using the univariate statistical approach, were analyzed more deeply using a repeated measures logistic regression model. We obtained significant results for neoplasia (odds ratio, 2.9; 95% confidence interval, 1.4 to 5.9; P ≤ 0.05) and prior use of fluconazole (odds ratio, 3.8; 95% confidence interval, 1.7 to 8.2; P ≤ 0.01). (Table 6 ).
www.intechopen.com Caspofungin and anidulafungin resistance was low (16 cases for caspofungin and 8 cases for anidulafungin) ( Table 4 ). Despite this low rate of in vitro resistance to echinocandins of the isolates studied MICs from C. parapsilosis and C. guilliermondi were higher compared to the MIC obtained from other Candida spp. as it has been described in others studies.
Antifungal treatment
At the time of diagnosis and inclusion in this study, 122 case patients (12.3%) were receiving a systemic antifungal agent and were considered breakthrough infections (fluconazole, 78 patients, amphotericin B, 31 patients, itraconazole and voriconazole, 3 patient each; and echinocandins, 5 patients). Although the reason for this high rate of breakthrough infections is not clear, it is possible that other factors besides the antifungal resistance have got a role in the explanation of this phenomenon. A deep analysis of these 122 cases showed that either the antifungal therapy duration or the election of the antifungal drug was inadequate. A total of 536 case patients (54.5%) received antifungal therapy, started at a median of 3 days from the Candida isolation or onset of candidemia.
Mortality
The crude mortality rate was 24.10%, but the mortality rate among children was significantly lower. (see Table 3 ) As it has been described in different studies published in the medical literature candidemia due to C. parapsilosis had a lower mortality rate than the rate due other Candida species (Morgan et 
Discussion and remarks
This prospective candidemia surveillance study represents one of the largest multicenter studies conducted in Spain and provide one of the most representative data on the epidemiology of candidemia to date. The first remarkable finding of our study was the higher incidence of candidemia than those reported from centers located in the Northern Hemisphere which ranged between 0.28 to 0. Table 7 ).
Country and period Despite this fact, it seems that probably a combination of factors may have affected the overall rates of fungemia cases in Spain. The differences appeared in the average age of our patients when compared to other surveillance series from the United States (OstroskyZeichner et al., 2003, Pappas et al., 2003) , are probably due to the high proportion of children in our study, especially in the Spanish hospitals located in the Southern part of the country (32% of children in the Spanish hospitals from the Southern part of the country compared to 9% described in the study from the United States) (data not shown). Therefore, this condition reflects that there are great differences among patients of different geographical locations as it was mentioned in the introduction and the demographical composition and lastly the risk factors, could be very different from one population to another. (Table 7) . In fact, the number of cases of invasive candidemia was not homogeneous across the country., the distribution of the clinical isolates obtained during the study period along four different geographical areas in Spain,. (North, Center, East and South). C. albicans covers almost half (49.08%) of the global cases, remaining as the most frequently isolated specie, but the rates between the four different areas were not homogenous., for instance, in the Southern part of the country the rate of isolates of C. albicans (39.2%) was similar to the one of C. parapsilosis (37.4%).
Some studies have reported a shift in the etiology of candidemia reporting an increase of candidemia cases caused by non-albicans Candida species during the last decade ( (Table 7 ). Although C. albicans remain the most frequently isolated specie, reasons for the emergence of non-albicans species remain unclear, but some medical conditions may explain increasing incidence of candidemia due to non-albicans species. It has been noted in previous reports that infections due to C. tropicalis candidemia is associated with neoplasia and neutropenia (Komshian et al., 1989) and . In fact, the differences in antifungal susceptibilities among isolates between different regions in Spain was almost entirely attributable to high-level resistance to azoles observed among C. glabrata and C. krusei isolates (Table 4) .
We are not aware of these epidemiological changes mentioned in the paragraph above and our findings from our study are supportive of them. C. parapsilosis fungemia account for the large majority of non-albicans species (in the same manner that that been described for other European countries) and candidemia due to C. krusei is rare in Spain as it has been described in other series ( While most non-albicans Candida species are associated with high fluconazole minimum inhibitory concentrations (MIC), C. parapsilosis is typically susceptible to most antifungals, although is associated with higher echinocandin MIC that vary between different agents. Moreover, the rate of persistently positive fungemia in patients treated with caspofungin was reported as almost double for C. parapsilosis versus other Candida species. Even more, if we consider clinical patients at risk of suffering a candidemia episode, such as Table 7 ). Mixing the ideas exposed above we can argue that the differences in the activity and susceptibility of the antifungal compounds studied suggest that azole drugs and echinocandins have got a complementary susceptibility profile. While azoles has got excellent in vitro activity to C. albicans, C. parapsilosis and C. tropicalis bloodstream isolates, echinocandins showed excellent activity against C. glabrata and C. krusei which are are associated with higher azole MICs. On the contrary, species with high MICs to echinocandins such as C. parapsilosis and C. guilliermondii showed excellent activity to azole agents. (Table 8 ). These ideas are of great importance because previous exposure to fluconazole was a strong and independent factor associated with candidemia caused by fluconazole non-susceptible isolates as it had been reported previously by Marr et al. and Lin and colleagues and higher voriconazole MICs tended to be associated with prior exposure to fluconazole. Although these obtained results are statistically significant, they must be taken with some caution because the low resistant proportion of isolates in our study. However, they depict a situation of concern and illustrate the potential problem of cross-resistance between azoles with a direct impact in treatment failure and the outcome of the patient. Moreover, the potential for voriconazole resistant C. glabrata to emerge as a threat in people receiving voriconazole therapy and or prophylaxis has been raised in reports of breakthrough infections (Imhof et al., 2004 , Pfaller et al., 2004 .
Specie of Candida
Despite these concerning matters exposed above, voriconazole was the azole which exhibited the best in vitro antifungal activity in our study, and only one of six fluconazoleresistant isolates was cross-resistant to voriconazole. The combination of a third generation azole such as voriconazole or posaconazole with an echinocandin could be of benefit for some patients, especially in those with persistent candidemia.
The crude mortality rate observed in our study was similar to that reported in other series ( Summarizing, the epidemiological and susceptible data described along the text, document important differences and similarities in the epidemiology of candidemia in Spain compared to updated reports from other countries. This report shows that candidemia is a source of significant morbidity and mortality with high associated healthcare costs. Although our high rates of candidemia may be related to many factors, reasons for them are not clear and further study is necessary. Determining them may lead to identify potential measures that can help in disease prevention. In addition, our data support that fluconazole nonsusceptibility could be associated with prior fluconazole exposure and suggest that such exposure could lead to other new azoles cross-resistance and complicate the clinical outcome of some patients.
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